212 related articles for article (PubMed ID: 18346175)
21. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG
Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505
[TBL] [Abstract][Full Text] [Related]
22. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
[TBL] [Abstract][Full Text] [Related]
24. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
25. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic parameters of bromperidol in Korean subjects.
Lee SY; Kim YG; Kim HG; Kim JW
Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
[TBL] [Abstract][Full Text] [Related]
27. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
28. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
29. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms.
van der Padt A; van Schaik RH; Sonneveld P
Neth J Med; 2006 May; 64(5):160-2. PubMed ID: 16702617
[TBL] [Abstract][Full Text] [Related]
30. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
Vandel P; Haffen E; Vandel S; Bonin B; Sechter D; Bizouard P; Dalery J
Therapie; 2000; 55(3):349-53. PubMed ID: 10967711
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.
Ozdemir V; Bertilsson L; Miura J; Carpenter E; Reist C; Harper P; Widén J; Svensson JO; Albers LJ; Kennedy JL; Endrenyi L; Kalow W
Pharmacogenet Genomics; 2007 May; 17(5):339-47. PubMed ID: 17429316
[TBL] [Abstract][Full Text] [Related]
32. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
[TBL] [Abstract][Full Text] [Related]
33. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.
Ellingrod VL; Schultz SK; Arndt S
Psychiatr Genet; 2000 Mar; 10(1):9-11. PubMed ID: 10909122
[TBL] [Abstract][Full Text] [Related]
34. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
[TBL] [Abstract][Full Text] [Related]
35. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.
Ouerhani S; Marrakchi R; Bouhaha R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Bull Cancer; 2008 Feb; 95(2):E1-4. PubMed ID: 18304900
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
[TBL] [Abstract][Full Text] [Related]
38. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?
Fernández-Santander A; Santiago C; Díez-Durán S; González M; de Castro E; Guijarro J; Bandrés F; Lucia A; Gómez-Gallego F
Hum Psychopharmacol; 2008 Aug; 23(6):533-6. PubMed ID: 18425996
[TBL] [Abstract][Full Text] [Related]
39. CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics.
Gonzalez-Tejera GM; Corey S
Bol Asoc Med P R; 2009; 101(1):7-12. PubMed ID: 19954080
[TBL] [Abstract][Full Text] [Related]
40. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.
Mihara K; Kondo T; Higuchi H; Takahashi H; Yoshida K; Shimizu T; Kaneko S
Am J Med Genet; 2002 Aug; 114(6):693-5. PubMed ID: 12210290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]